All News
Lento Bio Expands Leadership Team with the Appointment of Two Renowned Ophthalmology and Presbyopia Experts
SYRACUSE, NY, UNITED STATES, November 11, 2024 /EINPresswire.com/ — Lento Bio, a company dedicated to developing innovative eyedrops that address presbyopia by reducing lens stiffness,
Lento Bio Relocates to Syracuse, NY, Joining Ichor Life Sciences’ New Biotech Incubator Facility
SYRACUSE, NY, USA, June 3, 2024 /EINPresswire.com/ — Lento Bio, a preclinical pharmaceutical startup focused on developing eyedrops for the treatment of presbyopia, announced today
Lento Bio Announces Official Collaboration With Florida State University and Expansion of Advisory Board
POTSDAM, NY, USA, February 7, 2023/EINPresswire.com- Lento Bio, an early-stage pharmaceutical research company developing novel small molecule drugs for presbyopia, is proud to announce two
Lento Bio Raises $680,000 In Oversubscribed Seed Round Led by Ichor Life Sciences
POTSDAM, NY / September 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia
Lento Bio Appoints Two Ichor Life Sciences Executives as Members of The Board of Directors and Scientific Advisors
Potsdam, N.Y. – Lento Bio, Inc., a preclinical pharmaceutical company developing therapeutics to target molecular damage driving age-related disease, announced today it appointed Dr. Kelsey
Lento Bio, An Ichor Life Sciences Portfolio Company, Launches With Aims to Develop Anti-Glycation Drugs for Presbyopia and Diseases of Aging
Potsdam, N.Y. –. Lento Bio, Inc., a preclinical pharmaceutical company focused on developing small-molecule therapeutics to target molecular damage driving age-related disease, announced its launch